Technical Analysis for FRX - Fennec Pharmaceuticals Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 9.230 | 1.65% | 0.150 |
Earnings due: Aug 1
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Narrow Range Bar | Range Contraction | 0.00% | |
| Weak + Overbought | Other | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| Up 3 Days in a Row | Strength | 0.00% | |
| Up 4 Days in a Row | Strength | 0.00% | |
| Narrow Range Bar | Range Contraction | 1.65% | |
| Weak + Overbought | Other | 1.65% | |
| Inside Day | Range Contraction | 1.65% | |
| BB Squeeze Ended | Range Expansion | 1.65% |
| Alert | Time |
|---|---|
| Rose Above Previous Day's High | about 14 hours ago |
| 3x Volume Pace | about 14 hours ago |
| 2x Volume Pace | about 14 hours ago |
| Up 1% | about 14 hours ago |
| 1.5x Volume Pace | about 14 hours ago |
Get a Trading Sidekick!
- Earnings date: 2024-08-01
Fennec Pharmaceuticals Inc. Description
Fennec Pharmaceuticals Inc., formerly Adherex Technologies Inc., is a biopharmaceutical company focused on cancer therapeutics. The Company's lead product candidate in the clinical stage of development includes Sodium Thiosulfate (STS), which has completed patient enrollment of over two Phase III clinical trials for the prevention of cisplatin induced hearing loss, or ototoxicity in children. STS has been studied by cooperative groups in over two Phase III clinical studies of survival and reduction of ototoxicity, The Clinical Oncology Group Protocol ACCL0431 and SIOPEL 6. The Children's Oncology Group (COG) ACCL0431 protocol enrolled 20% childhood cancers typically treated with intensive cisplatin therapy for localized and disseminated disease, including hepatoblastoma, germ cell tumor, osteosarcoma, neuroblastoma and medulloblastoma. SIOPEL 6 enrolled only hepatoblastoma patients with localized tumors.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Pharma Pharmaceutical Clinic Disease Cancer RTT Pharmaceuticals Therapy Clinical Trial Oncology Biopharmaceutical Cancers Tumor Blastoma Tumors Brain Tumor Childhood Neoplasms
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 15.43 |
| 52 Week Low | 7.8 |
| Average Volume | 2,463 |
| 200-Day Moving Average | 11.363 |
| 50-Day Moving Average | 9.386 |
| 20-Day Moving Average | 8.626 |
| 10-Day Moving Average | 9.009 |
| Average True Range | 0.281 |
| RSI (14) | 54.34 |
| ADX | 20.61 |
| +DI | 36.828 |
| -DI | 25.209 |
| Chandelier Exit (Long, 3 ATRs) | 8.428 |
| Chandelier Exit (Short, 3 ATRs) | 8.642 |
| Upper Bollinger Bands | 9.517 |
| Lower Bollinger Band | 7.734 |
| Percent B (%b) | 0.84 |
| BandWidth | 20.664 |
| MACD Line | -0.080 |
| MACD Signal Line | -0.230 |
| MACD Histogram | 0.1504 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 9.275 | ||||
| Resistance 3 (R3) | 9.270 | 9.250 | 9.268 | ||
| Resistance 2 (R2) | 9.250 | 9.239 | 9.253 | 9.265 | |
| Resistance 1 (R1) | 9.240 | 9.231 | 9.245 | 9.245 | 9.262 |
| Pivot Point | 9.220 | 9.220 | 9.223 | 9.223 | 9.220 |
| Support 1 (S1) | 9.210 | 9.209 | 9.215 | 9.215 | 9.198 |
| Support 2 (S2) | 9.190 | 9.201 | 9.193 | 9.195 | |
| Support 3 (S3) | 9.180 | 9.190 | 9.193 | ||
| Support 4 (S4) | 9.185 |
